Table 3 The additive interaction between conventional risk factors and areca nuts use for coronary artery disease
Factors/Category | Healthy controls (n = 720) N (%) | Obstructive CAD (n = 293) N (%) | Adjusted OR (95% CI)c | Additive interactiona,b | ||
|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | EORa | SIb(95% CI) |
Smoke/Areca nuts use | Â | Â | Â | Â | Â | Â |
   Never/Never | 410 (56.9) | 73 (24.9) | 1.0 |  |  |  |
   Ever/Never | 253 (35.1) | 132 (45.1) | 3.8 | (2.4-6.1) |  |  |
   Never/Ever | 4 (0.6) | 3 (1.0) | 1.5 | (0.2-13.5) |  |  |
   Ever/Ever | 53 (7.4) | 85 (29.0) | 15.0 | (7.8-28.9) | 4.3 | 4.3 (1.3-13.7) |
Diabetes/Areca nuts use | Â | Â | Â | Â | Â | Â |
   Never/Never | 591 (82.1) | 128(43.7) | 1.0 |  |  |  |
   Ever/Never | 72 (10.0) | 77 (26.3) | 2.6 | (1.5-4.3) |  |  |
   Never/Ever | 47 (6.5) | 50 (17.1) | 3.6 | (1.9-6.9) |  |  |
   Ever/Ever | 10 (1.4) | 38 (12.9) | 10.4 | (4.1-26.3) | 5.2 | 2.2 (0.7-6.8) |
Hypertension/Areca nuts use | Â | Â | Â | Â | Â | Â |
   Never/Never | 528(73.3) | 51(17.4) | 1.0 |  |  |  |
   Ever/Never | 135(18.8) | 154(52.6) | 9.7 | (6.0-15.6) |  |  |
   Never/Ever | 48 (6.7) | 23 (7.8) | 3.2 | (1.5-6.5) |  |  |
   Ever/Ever | 9 (1.3) | 65 (22.2) | 45.5 | (19.0-109.2) | 11.9 | 4.1 (1.7-9.7) |
Dyslipidemia/Areca nuts use | Â | Â | Â | Â | Â | Â |
   Never/Never | 560(77.8) | 53(18.1) | 1.0 |  |  |  |
   Ever/Never | 103(14.3) | 152(51.9) | 13.0 | (8.2-20.6) |  |  |
   Never/Ever | 50 (6.9) | 36 (12.3) | 3.9 | (2.0-7.5) |  |  |
   Ever/Ever | 7 (1.0) | 52 (17.7) | 44.4 | (17.1-115.2) | 15.9 | 2.9 (1.1-7.7) |